Intra-articular steroid injections for lumbar disk herniation: a systematic review and meta-analysis

腰椎间盘突出症的关节内类固醇注射:系统评价和荟萃分析

阅读:2

Abstract

INTRODUCTION: Lumbar disc herniation (LDH) is one of the most common causes of lower back pain, radiculopathy, and functional impairment. Intra-articular (IA) steroid injections, including transforaminal (TFESI), interlaminar (IESI), and caudal (CESI) epidural steroid injections, are commonly administered to alleviate these symptoms when surgery is not indicated or opted for. This systematic review and meta-analysis evaluates the efficacy of these injection modalities in reducing pain and disability in LDH patients. METHODS: Following PRISMA, 19,664 studies on IA steroid injections for LDH were screened, yielding 41 eligible studies. Random-effects and fixed effects meta-analyses computed pooled standardized mean changes (SMC), depending on heterogeneity (I(2)). RESULTS: TFESI showed strong short-term efficacy, with the greatest pooled NRS improvement of -5.15 (95% CI: -6.59, -3.72, p < 0.001, I(2) = 99.14%) at 3 months and the largest VAS reduction of -30.53 (95% CI: -43.89, -17.17, p < 0.001, I(2) = 99.99%) at 3 months. CESI had the highest ODI improvement at 1 month (-18.99, 95% CI: -26.88, -11.10, p < 0.001, I(2) = 99.35%), while IESI demonstrated the greatest ODI reduction at 6 months (-16.06, 95% CI: -16.83, -15.28, p < 0.001, I(2) = 18.85%). CONCLUSION: This meta-analysis suggests that IA injections may relieve LDH symptoms, with TFESI showing the greatest pain relief and functional improvement. However, significant heterogeneity calls for standardized protocols and further research. Demographic factors minimally influenced outcomes, whereas methodological variability underscores treatment complexity. Future studies should emphasize methodological consistency and personalized approaches to optimize patient outcomes.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。